Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL40626S in Healthy Adult Participants
NCT07736586Phase 1Recruiting
- Sponsor
- Highslab Therapeutics
- Start
- Aug 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HL40626S in psoriasis (4 arms), sponsored by Highslab Therapeutics. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at Day 29, Incidence of serious adverse events at Day 29 and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
HL40626S
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT07736586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07736586.